Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5-year results of the randomized CLL14 study

The 5-year updated data from the phase 3 CLL14 trial examining venetoclax plus obinutuzumab vs. chlorambucil plus obinutuzumab for treatment-naive patients with CLL was presented at the European Hematology Association (EHA) 2022 Congress. At a median follow up of 65.4 months, progression-free survival (PFS) for venetoclax/obinutuzumab was significantly superior (median, not reached vs. 36.4 months; P < 0.0001), as was the time-to-next-treatment rate (72.1% vs. 42.8%) across all risk groups. The estimated 5-year progression free survival (PFS) was 62.6% for patients who received venetoclax plus obinutuzumab vs. 27.0% for those who received chlorambucil plus obinutuzumab.